Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms.
Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms.
复制标题
垂体腺苷酸环化酶激活多肽 PACAP-38 和 PACAP-27，通过激活 I 型 PACAP/VIP 受体亚型调节交感神经元儿茶酚胺和神经肽 Y 表达。
DOI：
10.1111/j.1749-6632.1996.tb17484.x
复制
发表时间：
1996
影响因子：
5.2
通讯作者：
May,V
中科院分区：
文献类型：
--
作者：
Braas,KM;May,V
目前的研究表明 PACAP 肽在调节交感肾上腺谱系细胞的生理功能中发挥着重要作用。与 VIP 相比，PACAP-27 和 PACAP-38 对交感神经元 NPY 和儿茶酚胺的产生具有强效、有效和持续的刺激作用。 PACAP 肽对 SCG NPY 和儿茶酚胺含量和分泌的不同影响与之前直接激活交感细胞内环 AMP-蛋白激酶 A 信号通路的研究相一致。这些效应似乎主要是由 SCG 神经元中与腺苷酸环化酶和磷脂酶 C 偶联的 PACAP1 受体剪接变体介导的。 PACAP 肽在 SCG 中的作用与肾上腺髓质嗜铬细胞有许多相似之处，表明 PACAP 肽能系统在交感肾上腺细胞发育和功能中发挥着不同的作用。这些结果不是解决方案，而是对未来提出了更多问题。调节交感神经和肾上腺功能的 PACAP 的内源性来源是什么？ PACAP 肽是否像 VIP 一样具有双重作用并且还充当交感神经节后神经调节剂？ VIP/PACAP 受体在 SCG 发育过程中是否表达？是什么调节交感神经 PACAP1 受体异构体的表达以及它们如何与神经元细胞内信号级联反应有差异地耦合？ PACAP-27 和 PACAP-38 的组织特异性反应的定义是什么？虽然其中许多问题并不容易解决，但未来对这些问题的研究肯定会阐明 PACAP 和 PACAP 受体在神经和内分泌系统中的功能。
The current studies have implicated a prominent role for PACAP peptides in modulating the physiological function of cells derived from the sympathoadrenal lineage. Compared to VIP, both PACAP-27 and PACAP-38 demonstrated potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. The differential effects of PACAP peptides on SCG NPY and catecholamine content and secretion coincided with previous studies that activated directly the sympathetic intracellular cyclic AMP-protein kinase A signaling pathway. These effects appear to be mediated primarily by PACAP1 receptor splice variants coupled to both adenylyl cyclase and phospholipase C in SCG neurons. The actions of PACAP peptides in the SCG shared many parallels with adrenal medullary chromaffin cells, suggesting diverse roles for the PACAP peptidergic system in sympathoadrenal cell development and function. Rather than solutions, these results pose additional questions for the future. What are the endogenous sources of PACAP that regulate sympathetic and adrenal function? Do PACAP peptides, like VIP, have dual roles and also act as sympathetic postganglionic neuromodulators? Are VIP/PACAP receptors expressed during SCG development? What regulates sympathetic PACAP1 receptor isoform expression and how are they differentially coupled to neuronal intracellular signaling cascades? What defines the tissue-specific responses to PACAP-27 and PACAP-38? While many of these questions are not easily approached, future studies of these issues will certainly illuminate the function of PACAP and PACAP receptors in the nervous and endocrine systems.